DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors

Terminated

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

First Posted Date: 2008-07-04

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00710151

Locations: 🇩🇪
Charite University Medicine, Berlin, Germany
🇩🇪
University Medical Center, Freiburg, Germany
🇩🇪
University of Bochum, Bochum, Germany

and more 1 locations

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: clofarabine
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: polymerase chain reaction
Other: high performance liquid chromatography
Other: laboratory biomarker analysis

First Posted Date: 2008-06-05

Last Posted Date: 2019-11-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00691652

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors

Not Applicable

Completed

Conditions: Fatigue
Breast Cancer
Cancer Survivor
Long-term Effects Secondary to Cancer Therapy in Adults
Psychosocial Effects of Cancer and Its Treatment

Interventions: Other: laboratory biomarker analysis
Behavioral: exercise intervention
Other: questionnaire administration
Other: survey administration
Procedure: assessment of therapy complications
Procedure: fatigue assessment and management
Procedure: management of therapy complications
Procedure: psychosocial assessment and care

First Posted Date: 2008-04-21

Last Posted Date: 2015-10-15

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 115

Registration Number: NCT00662103

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Exercise for Physical Health in Men With Prostate Cancer

Not Applicable

Completed

Conditions: Prostatic Neoplasm
Osteoporosis

Interventions: Behavioral: Flexibility Training
Behavioral: Resistance Exercise

First Posted Date: 2008-04-17

Last Posted Date: 2015-10-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 56

Registration Number: NCT00660686

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Not Applicable

Completed

Conditions: Adult Brain Glioblastoma

Interventions: Drug: Gadolinium
Drug: Ferumoxytol Non-Stoichiometric Magnetite
Other: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Other: Diffusion Weighted Imaging
Other: MRI-Based Angiogram

First Posted Date: 2008-04-17

Last Posted Date: 2017-05-16

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 14

Registration Number: NCT00660543

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Optimizing Body Composition & Health After Breast Cancer

Not Applicable

Completed

Conditions: Breast Neoplasm
Osteoporosis, Postmenopausal

Interventions: Behavioral: Flexibility Training
Behavioral: Resistance Exercise

First Posted Date: 2008-04-17

Last Posted Date: 2015-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 71

Registration Number: NCT00659906

Locations: 🇺🇸
OHSU School of Nursing, Portland, Oregon, United States

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

Phase 2

Terminated

Conditions: Brain Neoplasms

Interventions: Drug: Ferumoxtran-10 (Combidex)
Procedure: Neurosurgery

First Posted Date: 2008-04-16

Last Posted Date: 2022-12-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 116

Registration Number: NCT00659334

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Phase 2

Terminated

Conditions: Metastatic Malignant Neoplasm in the Brain
Primary Brain Neoplasm

Interventions: Procedure: 3 Tesla Magnetic Resonance Imaging
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol
Drug: Gadolinium
Procedure: High Field Strength Magnetic Resonance Imaging
Procedure: Susceptibility Weighted Imaging

First Posted Date: 2008-04-16

Last Posted Date: 2023-09-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00659126

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Erlotinib
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2008-03-25

Last Posted Date: 2014-09-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00642746

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

Not Applicable

Completed

Conditions: Breast Cancer
Precancerous Condition

Interventions: Other: placebo
Dietary Supplement: omega-3 fatty acid

First Posted Date: 2008-03-03

Last Posted Date: 2017-04-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00627276

Locations: 🇺🇸
Epic Imaging, Portland, Oregon, United States
🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy